Tharimmune Inc. (THAR)
2.01
0.05 (2.55%)
At close: Jan 15, 2025, 3:58 PM
1.99
-1.00%
After-hours Jan 15, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 1.99 |
| Market Cap | 2.99M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 61.01 |
| PE Ratio (ttm) | 0.03 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.05 |
| Volume | 6,701 |
| Avg. Volume (20D) | 1,310,591 |
| Open | 2.02 |
| Previous Close | 1.96 |
| Day's Range | 1.98 - 2.06 |
| 52-Week Range | 1.83 - 7.71 |
| Beta | undefined |
About THAR
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed c...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 12, 2022
Employees 2
Stock Exchange NASDAQ
Ticker Symbol THAR
Website https://www.tharimmune.com
Analyst Forecast
According to 1 analyst ratings, the average rating for THAR stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 745.73% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
+10.84%
Tharimmune shares are trading higher after it anno...
Unlock content with
Pro Subscription
2 months ago ·
Source
+68.97%
Tharimmune shares are trading higher after the company announced it received EMA feedback on its TH104 clinical program. The design and main features of the proposed Phase 2 study were deemed acceptable and general guidance was also provided for a future Phase 3 study.
